Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
August 24, 2022 15:00 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has...
Alaunos Therapeutics Reports Second Quarter 2022 Financial Results
August 15, 2022 07:00 ET
|
Alaunos Therapeutics, Inc.
Advancing TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; plan to present early data in 3Q 2022 at a scientific conference; moving ahead with...
Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
August 08, 2022 08:50 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the second quarter ended...
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations
August 04, 2022 17:00 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced the...
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025
June 27, 2022 08:00 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, June 27, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the...
Alaunos Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2022 08:30 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin...
Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
May 26, 2022 17:01 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in...
Alaunos Therapeutics Reports First Quarter 2022 Financial Results
May 16, 2022 07:30 ET
|
Alaunos Therapeutics, Inc.
Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present preclinical data today at the ASGCT 25th...
Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 10, 2022 08:30 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced that Kevin S....
Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
May 09, 2022 08:30 ET
|
Alaunos Therapeutics, Inc.
HOUSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the first quarter ended...